AMGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 308.2 USD | -0.07% |
|
+3.00% | +7.09% |
| 05-13 | Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating | MT |
| 05-09 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 105 M€ | +3.29% | - | |
| 0.09% | 17 M€ | +2.84% | - | |
| 0.09% | 6 M€ | +3.89% | ||
| 0.06% | 26 M€ | +16.85% | - | |
| 0.05% | 54 M€ | +0.30% | - | |
| 0.05% | 23 M€ | +12.29% | - | |
| 0.04% | 8 M€ | +0.60% | - | |
| 0.04% | 6 M€ | -4.26% | - | |
| 0.04% | 234 M€ | +2.60% | - | |
| 0.02% | 34 M€ | +3.39% | - | |
| 11.86% | 129 M€ | +6.44% | - | |
| 15.31% | 28 M€ | +5.06% | - | |
| 211.11% | 67 M€ | +1.85% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
308.4
USD
Average target price
314.6
USD
Spread / Average Target
+2.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.09% | 165B | |
| +29.98% | 682B | |
| +30.77% | 586B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.75% | 240B | |
| +9.76% | 209B | |
| -8.51% | 203B | |
| -1.22% | 161B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.
